ArticleEuropean journal of medical research2025
Clinical significance of androgen receptor in unilateral invasive breast cancer in women.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the prognostic relevance of androgen receptor (AR) expression in patients following modified radical surgery for invasive breast cancer.
methodsA cohort of 515 patients who underwent modified radical mastectomy for breast cancer from July 2016 to November 2017 was analyzed. Immunohistochemistry was employed to determine the expression levels of AR, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER-2), cell proliferation nuclear antigen (Ki-67), oncogene (P-53), cytokeratin 5/6 (CK5/6), topoisomerase-2 (TOPO-2), and epidermal growth factor receptor (EGFR). The correlation between AR expression and clinicopathological features as well as prognosis was examined. Multifactorial analysis using Cox proportional risk regression identified independent prognostic factors for disease-free survival (DFS), and a nomogram model was developed based on these factors.
resultsPatients in the AR-positive group demonstrated a significantly higher frequency of low histologic grade (grade 1-2), ER positive, PR positive, TOPO-2-negative, CK5/6-negative, and EGFR-negative as compared to the AR-negative group (P < 0.05). Among ER( +)/HER-2(-) and ER( +)/HER-2( +) patients with breast cancer, AR-positive individuals exhibited prolonged DFS (P < 0.05). Conversely, in ER(-)/HER-2( +) and ER(-)/HER-2(-) patients with breast cancer, AR expression did not significantly influence disease-free survival (P > 0.05). Multifactorial regression analysis identified AR/ER ratio, histological classification, and lymph node metastasis as independent prognostic factors for DFS (all P < 0.05). The developed nomogram model underscored the significance of histological classification as the primary predictive factor for patient outcomes, followed by AR/ER ratio and lymph node metastasis
conclusionAR expression holds varying prognostic implications across different breast cancer subtypes, with AR positivity indicating a favorable prognosis, particularly in ER-positive tumors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.